Furthermore, durable clinical responses were obtained when PBMC-derived tumor-reactive T cells, comprising almost exclusively clonally expressed neoepitope-specific CD8+ and CD4+ T cells, were infused (10, 11, 16). The gene discussed is CD4; the disease is neoplasm.